Ratings Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq Other stock markets 04:00:08 2024-05-17 pm EDT			5-day change	1st Jan Change
2.12 ^USD	-1.85%		+11.58%	-36.34%

May. 13	Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	MT
May. 09	Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
COHERUS BIOSCIENCES, INC.	-36.34%	243M	C-
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B	B+
ARGENX SE	-2.71%	21.96B	B
BIONTECH SE	-14.15%	21.87B	B+
GENMAB A/S	-5.29%	19.21B	A-
BEIGENE, LTD.	-4.16%	18.08B	B
WUXI APPTEC CO., LTD.	-38.29%	17.71B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B	C+
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes